Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting CLK1/SRSF7 axis-dependent alternative splicing sensitizes pancreatic ductal adenocarcinoma to chemotherapy and immunotherapy

18 Aug 2025

Abstract excerpt

AIM: The persistently high mortality rate of pancreatic ductal adenocarcinoma (PDAC) is largely attributed to the acquired resistance to chemotherapy, particularly gemcitabine. This study aims to elucidate the underlying molecular mechanisms of gemcitabine resistance in PDAC, uncover additional pro-tumorigenic factors contributing to drug resistance, and develop more effective and safer targeted therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Cancer-related molecular mechanisms research
Share to Circular RNAs in diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40840404
DOI: 10.1016/j.drup.2025.101292

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting CLK1/SRSF7 axis-dependent alternative splicing sensitizes pancreatic ductal adenocarcinoma to chemotherapy and immunotherapyPMID 40840404Read ↗

Small non-coding RNAs and pancreatic ductal adenocarcinoma: Linking diagnosis, pathogenesis, drug resistance, and therapeutic potentialSemantic proximity Read ↗

hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Noncoding RNAs in drug-resistant pancreatic cancer: A reviewSemantic proximity Read ↗

Unveiling Pharmacogenomics Insights into Circular RNAs: Toward Precision Medicine in Cancer TherapySemantic proximity Read ↗

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancerSemantic proximity Read ↗

Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1Semantic proximity Read ↗

Circ_0058058 Drives the Malignant Phenotypes and Immune Evasion of Pancreatic Cancer by the MicroRNA-557-Dependent Regulation of PDL1.Semantic proximity Read ↗

Circular RNAs as Targets for Developing Anticancer TherapeuticsSemantic proximity Read ↗

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.Semantic proximity Read ↗

Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT 1 to miR1207Semantic proximity Read ↗

Microarray analysis of circular RNA expression profiles associated with gemcitabine resistance in pancreatic cancer cellsSemantic proximity Read ↗

CircFOXK2 Promotes Tumor Growth and Metastasis of Pancreatic Ductal Adenocarcinoma via Complexing with RNA Binding Proteins and Sponging MiR-942Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.